ReNerve and VivaZome have entered a collaboration to combine their leading scaffold and exosome technologies, skills and experience to explore new solutions for the repair of spinal cord injuries.  The two companies will work together to explore the potential of combining the ReNerve NervAlign® nerve cuff with VivaZome’s proprietary exosomes to enhance nerve regrowth in damaged spinal cords. The NervAlign® nerve cuff has potential to facilitate localised delivery of regenerative factors to damaged nerves whilst protecting the healing process, while the VivaZome exosomes have potential to stimulate the regeneration of functional neural tissue and reduce inflammation. Read more at http://vivazome.com/wp-admin/post.php?post=3028&action=edit

Viva Zome CEO David Haylock is presenting at the Annual Conference of the American Society of Gene and Cell Therapy on 13 May 2021 in an Industrial Symposium sponsored by Pall Corporation. His presentation is entitled “Exosome manufacture in a fixed-bed bioreactor, and overcoming production challenges” Read more at http://vivazome.com/wp-content/uploads/2021/05/VivaZome-ASGCT-release-11-May-2021.pdf

VivaZome Therapeutics Pty Ltd and La Trobe University today announced that they have entered into a new collaborative research project focussed on developing novel exosome therapeutics. Under the collaborative arrangement, VivaZome scientists will work alongside members of Professor Andrew Hill’s laboratory in the La Trobe Institute for Molecular Science (LIMS). Professor Hill is one of the world’s pre-eminent exosome researchers, and a member of the La Trobe Research Centre for Extracellular Vesicles, with its extensive suite of specialised technology and high-level expertise.

Click to read full media release. http://vivazome.com/wp-content/uploads/2021/02/VivaZome-La-Trobe-Uni-release-16-Feb-2021.pdf

BIA’s unique CIM (Convective Interaction Media) monolith chromatography technology will be used to purify exosomes from VivaZome’s cell cultures, with the aim of developing a high-efficiency downstream purification and concentration process for exosome production.  

Click to read full media release. http://vivazome.com/wp-content/uploads/2021/01/VivaZome-BIA-release-21-Dec-2020.pdf

VivaZome features in lead article in International BioPharmaceutical Industry journal. “Exosome Therapeutics: Academic Curiosity or Commercial Reality” written by VivaZome CEO David Haylock and key academic collaborator Prof Andy Hill (La Trobe Uni). 

Click here to read article: 2020-IBI_Summer-Vivazome

VivaZome’s David Haylock says his company’s decision to base themselves in the Research & Innovation Precinct at La Trobe University revolved largely around one key researcher. Read the full story here 

https://www.latrobe.edu.au/industry-and-community/industry-partner-of-choice/research-and-innovation-precinct/precinct-partner-spotlight/vivazome

VivaZome features in “Inspire” – Research Australia’s Showcase for Health and Medical Research and Innovation.  Download the article here:

INSPIRE_20Jun2020

Under the agreement, VivaZome will provide substantial quantities of exosome-rich, cell culture supernatant produced by VivaZome’s preferred cell type. Cytiva’s Next Generation Resins Team, located in Uppsala in Sweden, will use the VivaZome material to evaluate Cytiva chromatography resins and fibre materials for their potential to separate and concentrate exosomes, with an emphasis on demonstrating high purity, very fast flow rates and scale-ability.

Read full media release here

Under the Licence Agreement, VivaZome has secured world-wide rights to intellectual property for the selection, isolation, purification, expansion and processing of stem cells from certain human tissues suitable for production of subcellular fractions. VivaZome will process these fractions to generate exosome products.

Read full media release here

Under the pilot study, ToolGen undertook a knock-down gene editing using its CRISPR/Cas9 technology, with the gene and the cell specified by VivaZome. The gene editing was successfully accomplished and exosome production by the edited cells was maintained at high levels.
The nest aim to create a gene-edited cell that could be used in VivaZome’s exosome manufacturing process.

Read the full media release here